Bortezomib
Product Description
Omnicap GmbH
-
Country/Region:Switzerland
-
On CPHI since:2017
-
Employees:1 - 24
Company types
Categories
Omnicap GmbH
-
Country/Region:Switzerland
-
On CPHI since:2017
-
Employees:1 - 24
Company types
More Products from Omnicap GmbH (99)
-
Product Anastrozole
Non-steroidal aromatase inhibitor API used in endocrine therapy for hormone-sensitive breast cancer. -
Product Ascorbic Acid
Vitamin C API and nutritional ingredient used for supplementation, antioxidant activity and correction of vitamin C deficiency. -
Product Azacitidine
Hypomethylating nucleoside analogue API used as an antineoplastic agent in myelodysplastic syndromes and acute myeloid leukemia. -
Product Balsalazide Disodium
Colon-targeted prodrug of mesalazine used as an anti-inflammatory treatment for ulcerative colitis. -
Product Bendamustine
Alkylating antineoplastic API used in the treatment of selected leukemias and lymphomas. -
Product Bicalutamide
Non-steroidal androgen-receptor antagonist API used in hormonal treatment of prostate cancer. -
Product Busulfan
Alkylating antineoplastic API used in leukemia therapy and conditioning regimens before hematopoietic stem-cell transplantation. -
Product Cabazital
Taxane-class microtubule inhibitor API used in oncology, particularly for advanced prostate cancer. -
Product Cabergoline
Long-acting dopamine D2 receptor agonist API used primarily to reduce elevated prolactin levels. -
Product Carbocisteine
Mucoregulating and mucolytic API used to reduce the viscosity of respiratory mucus. -
Product Carboplatin
Platinum-based cytotoxic antineoplastic API used in chemotherapy regimens for multiple solid tumors. -
Product Carfilzomib
Selective proteasome inhibitor API used mainly in the treatment of multiple myeloma.